updated 5/4/2011 4:16:53 PM ET 2011-05-04T20:16:53

BETHLEHEM, Pa., May 4, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced total revenues of $17.4 million for the three months ended March 31, 2011, compared to $17.9 million recorded for the three months ended March 31, 2010.

Product revenues for the quarter increased 3% as higher sales of the Company's infectious disease and substance abuse testing products were partially offset by lower sales of its cryosurgical systems and insurance risk assessment products. The higher product revenues were offset by a reduction in licensing and product development revenues caused by the absence of a $1.0 million milestone payment received in the first quarter of 2010 under the terms of the Company's collaboration with Merck related to the development and promotion of the OraQuick® rapid HCV test.

The Company reported a net loss of $2.6 million, or $0.06 per share, for the first quarter of 2011, compared to a net loss of $2.2 million, or $0.05 per share, for the first quarter of 2010.

Cash used in operating activities for the three months ended March 31, 2011 was $2.0 million, an improvement of $3.0 million when compared to the $5.0 million used during the three months ended March 31, 2010.

"Our financial results for the first quarter came in better than expected," said Douglas A. Michels, President and CEO of OraSure Technologies, Inc. "We exceeded our guidance for both revenues and the bottom line. Despite continued economic and funding challenges, we made solid progress on our goals for the quarter, including the ongoing clinical development of our OraQuick® HIV OTC test, which is a testament to the quality of our team."

Gross margin in the first quarter of 2011 was 65%, compared to 64% in the first quarter of 2010. Gross margin for the current period benefited from increased manufacturing efficiencies and a more favorable product mix.

Operating expenses for the first quarter of 2011 increased to $13.8 million, from $13.6 million in the comparable period of 2010, primarily as a result of higher research and development expenses due to clinical trial spending related to the Company's OraQuick® HIV over-the-counter product study. This increase was partially offset by lower sales and marketing and general and administrative expenses.

Cash, cash equivalents and short-term investments totaled $72.4 million and working capital was $76.0 million at March 31, 2011, compared to $75.7 million and $77.8 million, respectively, at December 31, 2010.

Second Quarter 2011 Outlook

The Company expects total revenues for the second quarter of 2011 to range from approximately $17.75 to $18.25 million. The Company is currently projecting a loss per share for the second quarter of 2011 of approximately $0.07 to $0.08.

Financial Data

  

  Condensed Financial Data
  (In thousands, except per‑share data)
  (Unaudited)
   
  Three months ended March 31,
  2011 2010
Results of Operations    
Revenues $17,414 $17,945
Cost of products sold 6,147 6,541
Gross profit 11,267 11,404
Operating expenses:    
Research and development 4,420 3,107
Sales and marketing 4,932 5,694
General and administrative 4,468 4,779
Total operating expenses 13,820 13,580
Operating loss (2,553) (2,176)
Other expense (45) (19)
Pre-tax loss (2,598) (2,195)
Income tax benefit 
Net loss  $ (2,598)  $ (2,195)
Loss per share  $ (0.06)  $ (0.05)
Basic and diluted
Weighted average shares:    
Basic and diluted 46,518 46,112
   
   
  Three months ended March 31,
      Percentage of
  Dollars % Total Revenues 
Market Revenues (Unaudited) 2011 2010 Change 2011 2010
           
Infectious disease testing $9,962 $9,481 5% 57% 53%
Substance abuse testing 3,061 2,713 13 18 15
Cryosurgical systems 2,710 2,994 (9) 15 17
Insurance risk assessment 1,317 1,384 (5) 8 7
Product revenues 17,050 16,572 3 98 92
Licensing and product development 364 1,373 (73) 2 8
Total revenues $17,414 $17,945 (3)% 100% 100%
       
    Three months ended  
    March 31, %
OraQuick ® HIV Revenues   2011 2010 Change
Domestic   $8,866 $8,733 2%
International   698 324 115%
Total OraQuick® HIV revenues   $9,564 $9,057 6%
         
         
    Three months ended  
    March 31, %
Intercept ® Revenues   2011 2010 Change
Domestic   $1,877 $1,528 23%
International   519 517
Total Intercept® revenues   $2,396 $2,045 17%
         
         
    Three months ended  
Cryosurgical Systems   March 31, %
Revenues   2011 2010 Change
Professional domestic   $1,342 $1,210 11%
Professional international   339 270 26
Over-the-counter   1,029 1,514 (32)
Total cryosurgical systems        
 revenues   $2,710 $2,994 (9)%
       
       
Balance Sheets (Unaudited) March 31, 2011   December 31, 2010
Assets      
Cash, cash equivalents and short-term $72,439   $75,738
investments      
Accounts receivable, net 12,120   12,471
Inventories 7,750   7,346
Other current assets 1,938   1,930
Property and equipment, net 19,850   19,611
Other non-current assets 5,096   5,424
Total assets $119,193   $122,520
       
Liabilities and Stockholders' Equity      
Current portion of long-term debt $7,667   $7,791
Accounts payable 3,506   2,899
Accrued expenses 7,048   8,987
Stockholders' equity 100,972   102,843
Total liabilities and stockholders' equity $119,193   $122,520
       
  Three months ended
   March 31, 
Additional Financial Data (Unaudited) 2011   2010
       
Capital expenditures $882   $532
Depreciation and amortization $829   $650
Stock based compensation $973   $891
Cash used in operating activities $2,049   $5,004
Accounts receivable – days sales      
outstanding 63 days   61 days

Conference Call

The Company will host a conference call and audio webcast to discuss the Company's 2011 first quarter financial results, business developments and certain 2011 financial guidance, beginning today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). On the call will be Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Chief Financial Officer and Chief Operating Officer. The call will include prepared remarks by management and a question and answer session.

In order to listen to the conference call, please either dial 877-348-9357 (Domestic) or 970-315-0488 (International) and reference Conference ID #61775799, or go to OraSure Technologies' web site, www.orasure.com, and click on the Investor Info link. A replay of the call will be archived on OraSure Technologies' web site shortly after the call has ended and will be available for seven days. A replay of the call can also be accessed until May 11, 2011, by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering the Conference ID #61775799.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices and tests and other diagnostic products using proprietary technologies, including immunoassays and other in vitro diagnostic tests and other medical devices. These products are sold in the United States and certain foreign countries to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. For more information on the Company, please visit www.orasure.com .

The OraSure Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6440

Important Information

This press release contains certain forward-looking statements, including with respect toexpected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through an internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts or minimum purchase requirements for the Company's products; impact of replacing distributors and success of direct sales efforts; inventory levels at distributors and other customers; impact of competitors, competing products and technology changes; impact of the economic downturn, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance, extended shelf life or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical product components; availability of related products produced by third parties or products required for use of our products; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of our stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; loss or impairment of sources of capital; ability to meet financial covenants in agreements with financial institutions; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; ability to identify, complete and realize the full benefits of potential acquisitions; and general political, business and economic conditions. These and other factors are discussed more fully in the Company's  Securities and Exchange Commission filings, including its registration statements, Annual Report on Form 10-K for the year ended December 31, 2010, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

CONTACT: Ronald H. Spair
         Chief Financial Officer
         610-882-1820
         Investorinfo@orasure.com
         www.orasure.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 5.09%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.67%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.34%
13.32%
Cash Back Cards 17.82%
17.81%
Rewards Cards 17.07%
17.06%
Source: Bankrate.com